Survey of Safety Information in the Investigator’s Brochure: Inconsistencies and Recommendations
Tóm tắt
A survey was undertaken to gain an understanding of current industry practices in the preparation of the safety information for the Investigator’s Brochure (IB). Sixteen of a potential 25 respondents completed a survey (64% response rate). Five respondents represented pharmaceutical and biotech companies, and 11 were consultants or worked at contract research organizations for such companies. The results showed a lack of uniformity of practices. This may be due to the lack of harmonized regulations and guidelines, the lack of standardized terminology and definitions, and the lack of clarity regarding the purpose and content of the various safety-related sections of the IB. These sections, although interrelated, have different purposes, and the criteria and methodology used have to be appropriate for these purposes. It is recommended that regulations, guidelines, and terminology be harmonized worldwide to enable consistent reporting to regulatory authorities across regions, minimize duplication of work for companies that operate in different regions, and to provide meaningful safety information both to the investigator and regulatory authorities. Recently published information regarding the format and the content of a “Reference Safety Information” section provides clarity for this element of the IB, which can hopefully be adopted globally. Until further regulatory clarity is provided for other safety sections, recommended approaches are provided.
Tài liệu tham khảo
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. Geneva, Switzerland: ICH; October 1994. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf. Accessed January 11, 2018.
IND Safety Reporting, 21 CFR 312.32; 2017.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. Rockville, MD: Food and Drug Administration; December 12 2012. https://www.fda.gov/downloads/Drugs/Guidances/UCM227351.pdf. Accessed January 11, 2018.
Clinical Trial Facilitation Group. Q&A document—reference safety information. http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2017_11_CTFG_Question_and_Answer_on_Reference_Safety_Information_2017.pdf. Published November 2017. Accessed January 11, 2018.
Clinical Trials Facilitation Group. Question and answers to the safety in clinical trials frequently asked questions regarding the reference safety information (RSI). http://ansm.sante.fr/var/ansm_site/storage/original/application/548683bde721c406f9c4c803b6d0087e.pdf. Published December 2013. Accessed January 11, 2018.
Labeling, 21 CFR 201.56; 2017.
European Commission. A guideline on summary of product characteristics (SmPC). http://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf. Published September 2009. Accessed January 11, 2018.
The European Parliament and the Council of the European Union. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Commun. 2001;L121:34–44. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF. Accessed January 11, 2018.
European Commission. Communication from the Commission. Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (“CT-3”). Off J Eur Commun. 2011;C132:1–13. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/2011_c172_01/2011_c172_01_en.pdf. Accessed January 11, 2018.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), annex I — definitions (rev 4). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143294.pdf. Published October 2017. Accessed January 11, 2018.
Council for International Organizations of Medical Sciences. Current Challenges in Pharmacovigilance: Pragmatic Approaches: Report of CIOMS Working Group V. Geneva, Switzerland: CIOMS; 2001.
Council for International Organizations of Medical Sciences. Management of Safety Information from Clinical Trials: Report of CIOMS Working Group VI. 1st ed. Geneva, Switzerland: CIOMS; 2005.
Council for International Organizations of Medical Sciences. Guidelines for Preparing Core Clinical-Safety Information on Drugs Report of CIOMS Working Group III & V. 2nd ed. Geneva, Switzerland: CIOMS; 1999.
Archdeacon P, Grandinetti C, Vega JM, Balderson D, Kramer JM. Optimizing expedited safety reporting for drugs and biologics subject to an investigational new drug application. Therapeutic Innovation & Regulatory Science. 2014;48:200–207.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Safety Assessment for IND Safety Reporting Guidance for Industry. Rockville, MD: Food and Drug Administration; December 2015. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM477584.pdf. Accessed January 11, 2018.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Date Report E2F. Geneva, Switzerland: ICH; August 2010. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2F/Step4/E2F_Step_4.pdf. Accessed January 11, 2018.